AstraZeneca presents new cancer data at AACR 2016

AstraZeneca is presenting new clinical data showcasing the efficacy of its new cancer drugs at this week's annual meeting of the American Association for Cancer Research (AACR).

The company is presenting 57 abstracts during the conference in New Orleans, in addition to five oral presentations and two lectures, plus participating in a roundtable session on PD-L1 diagnostic harmonisation.

Key highlights include new insights into AstraZeneca's industry-leading DNA damage response pipeline of potential medicines, which are currently undergoing early tests.

Andrew Mortlock, vice-president for global projects and alliances for oncology iMed at AstraZeneca, said: "With three new molecules now in the clinic and one on the market, we are following the science and exploring their potential in both monotherapy and in combination with other therapies."

Also to be showcased at the event are the company's newest immuno-oncology innovations, including data from a comparative study of commonly used PD-L1 diagnostic tests in approximately 500 tumour biopsies.

The firm is also presenting data on Tagrisso, exploring the utilisation of non-small cell lung cancer xenograft models from Tagrisso patients to refine therapeutic strategies.